{"title": "Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients", "doi": "10.1101/2020.03.22.20040774", "citation_id": "2020.03.22.20040774v1", "date": "2020-03-24", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.22.20040774", "abstract": "<p>Objectives: Comorbidities have significant indications for the disease outcome of COVID-19, however which underlying diseases that contribute the most to aggravate the conditions of COVID-19 patients is still largely unknown. SARS-CoV-2 viral clearance is a golden standard for defining the recovery of COVID-19 infections. To dissect the underlying diseases that could impact on viral clearance, we enrolled 106 COVID-19 patients who were hospitalized in the Zhongnan Hospital of Wuhan University, Wuhan, China between Jan 5 and Feb 25, 2020.\nMethodology: We comprehensively analyzed demographic, clinical and laboratory data, as well as patient treatment records. Survival analyses with Kaplan-Meier and Cox regression modelling were employed to identify factors influencing the viral clearance negatively. \nResults: We found that increasing age, male gender, and angiotensin-converting enzyme 2 (ACE2) associated factors (including hypertension, diabetes, and cardiovascular diseases) adversely affected the viral clearance. Furthermore, analysis by a random forest survival model pointed out hypertension, cortisone treatment, gender, and age as the four most important variables. \nConclusions: We conclude that patients at old age, males, and/or having diseases associated with high expression of ACE2 will have worse prognosis during a COVID-19 infections.</p>", "twitter_description": "Objectives: Comorbidities have significant indications for the disease outcome of COVID-19, however which underlying diseases that contribute the most to aggravate the conditions of COVID-19 patients is still largely unknown. SARS-CoV-2 viral clearance is a golden standard for defining the recovery of COVID-19 infections. To dissect the underlying diseases that could impact on viral clearance, we enrolled 106 COVID-19 patients who were hospitalized in the Zhongnan Hospital of Wuhan University, Wuhan, China between Jan 5 and Feb 25, 2020. Methodology: We comprehensively analyzed demographic, clinical and laboratory data, as well as patient treatment records. Survival analyses with Kaplan-Meier and Cox regression modelling were employed to identify factors influencing the viral clearance negatively. Results: We found that increasing age, male gender, and angiotensin-converting enzyme 2 (ACE2) associated factors (including hypertension, diabetes, and cardiovascular diseases) adversely affected the viral clearance. Furthermore, analysis by a random forest survival model pointed out hypertension, cortisone treatment, gender, and age as the four most important variables. Conclusions: We conclude that patients at old age, males, and/or having diseases associated with high expression of ACE2 will have worse prognosis during a COVID-19 infections.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nThis study was funded by the Zhongnan Hospital of Wuhan University, Science, Technology and Innovation Seed Fund, grant number znpy2018007 and the Swedish Research Council, grant number 2017-05807. The funders had no role in study design, data collection or analysis, decision to publish or preparation of the manuscript. The authors declared no competing interests.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data referred to in the manuscript are availability.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.22.20040774v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.22.20040774v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.22.20040774v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/24/2020.03.22.20040774.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.22.20040774v1", "access_rights": "restricted", "authors": ["Xiaoping Chen", "Wenjia Hu", "Jiaxin Ling", "Pingzheng Mo", "Yongxi Zhang", "Qunqun Jiang", "Zhiyong Ma", "Qian Cao", "Liping Deng", "Shihui Song", "Ruiying Zheng", "Shicheng Gao", "Hengning Ke", "Xien Gui", "\u00c5ke Lundkvist", "Jinlin Li", "Johanna F Lindahl", "Yong Xiong"]}